In the OGTT and ITT studies, treatment with EPPTB, a specific TAAR1 antagonist, significantly reduced tryptamine and phenethylamine-induced glucose intolerance and insulin resistance in mice (p < 0.05 in all cases, Fig. 6A–D). Here, TAAR1 is linked to Glucose intolerance.